Core Viewpoint - The stock of Valiant Pharmaceuticals-B (09887) has increased by over 5%, currently trading at 55.2 HKD with a transaction volume of 18.0035 million HKD, following the announcement of orphan drug designation for its dual-specific antibody, Viligene (Oparatuzumab, LBL-024) for the treatment of pulmonary neuroendocrine carcinoma by the European Commission [1] Group 1 - Valiant Pharmaceuticals-B's stock rose by 4.94% to 55.2 HKD as of the report [1] - The company reported a transaction volume of 18.0035 million HKD [1] - The European Commission granted orphan drug designation for Viligene on January 22, 2026, marking a significant milestone in its global development [1] Group 2 - This designation follows the previous orphan drug recognition by the U.S. Food and Drug Administration (FDA) [1] - The dual-specific antibody Viligene is aimed at treating pulmonary neuroendocrine carcinoma [1] - The orphan drug designation is a critical step in the drug's development process, enhancing its potential marketability and support [1]
维立志博-B涨超5% 维利信 获欧盟委员会授予孤儿药认定